Letter to the Editor: Repeat Redifferentiation of Radioiodine Refractory BRAF V600E Mutated Thyroid Cancer with Dabrafenib

Abstract

Get full access to this article

View all access options for this article.

References

Buffet

, Wassermann

, Hecht

, et al. Redifferentiation of radioiodine-refractory thyroid cancers. Endocr Relat Cancer, 2020; 27(5):R113–R132; doi: 10.1530/ERC-19-0491

Huillard

, Tenenbaum

, Clerc

, Goldwasser

, Groussin

. Restoring radioiodine uptake in BRAF V600E-mutated papillary thyroid cancer. J Endocr Soc, 2017; 1(4):285–287; doi: 10.1210/js.2016-1114

Busaidy

, Konda

, Wei

, et al. Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: Results of a randomized, phase 2, open-label multicenter trial. Thyroid, 2022; 32(10):1184–1192; doi: 10.1089/thy.2022.0115

Dorn

, Kopp

, Vogt

, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med, 2003; 44(3):451–456.

Jannin

, Lamartina

, Moutarde

, et al. Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive Iodine therapy and overall survival. Eur J Nucl Med Mol Imaging, 2022; 49:2401–2413; doi: 10.1007/s00259-022-05697-w